<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00498355</url>
  </required_header>
  <id_info>
    <org_study_id>FVF3872s</org_study_id>
    <nct_id>NCT00498355</nct_id>
  </id_info>
  <brief_title>Lucentis for Inflammatory Macular Edema Trial</brief_title>
  <acronym>LIME</acronym>
  <official_title>Effect of Ranibizumab on Refractory Macular Edema in Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Uveitis is an inflammation (swelling and irritation) inside the eye, affecting the uvea. The
      uvea is the layer of the eye between the sclera and the retina and provides most of the blood
      supply to the retina.

      Uveitis is an important cause of visual loss. There are 30,000 new cases of legal blindness
      each year due to uveitis in the U.S. Sight-threatening complications associated with uveitis
      include macular edema, which may persist even when inflammation is controlled. The only
      current treatment for cystoid macular edema (CME) in uveitis patients is oral or regional
      steroid injections. For patients who don't respond to steroids or who are unable to tolerate
      steroid therapy, there are no other medical treatments.

      The aim of this study is to determine if ranibizumab, an FDA-approved treatment for
      neovascular age-related macular degeneration, is an effective treatment for those patients
      with uveitis-induced CME who are unable to be treated with or non-responsive to steroids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uveitis, an inflammation that affects the uvea (iris, ciliary body and choroid), is an
      important cause of visual loss. There are 30,000 new cases of legal blindness each year due
      to uveitis in the U.S. Sight-threatening complications associated with uveitis include
      macular edema, which may persist even when inflammation is controlled. The only current
      treatment for cystoid macular edema (CME) in uveitis patients is oral or regional steroid
      injections. For patients who don't respond to steroids or who are unable to tolerate steroid
      therapy, there are no other medical treatments.

      The aim of the proposed research is to determine if ranibizumab is an effective treatment for
      those patients with uveitis-induced CME who are unable to be treated with or non-responsive
      to steroids. Ranibizumab is a recombinant, humanized monoclonal antibody antigen-binding
      fragment (Fab) that neutralizes all active forms of vascular endothelial growth factor
      (VEGF). VEGF is suspected to play a role in the loss of vascular integrity in the eye, which
      is thought to be involved in the pathogenesis of macular edema in the eyes of patients with
      uveitis. Ranibizumab was approved by the FDA for the treatment of neovascular age-related
      macular degeneration on June 30, 2006, and a number of published papers have shown efficacy
      for other causes of macular edema, including that due to diabetes mellitus.

      The F. I. Proctor Foundation at UCSF will be enrolling 10 subjects 18 years of age or older
      with uveitis-induced CME to clinically evaluate the safety and effectiveness of ranibizumab
      administered monthly for three months followed by PRN monthly dosing (up to 12 months). The
      study will measure visual acuity, changes in foveal thickness on optical coherence
      tomography, and changes in cystoid macular edema by fluorescein angiography to determine the
      efficacy of ranibizumab treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Mean Change at 3 Months in BSCVA From Baseline</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>The outcome measure was mean best spectacle-corrected visual acuity (BSCVA). In this study, BSCVA was measured after trial frame manifest refraction, using high-contrast modified Bailey-Lovie (ETDRS) charts at 4 meters. The charts were placed in a retro-illuminated light box equipped with two 20-watt fluorescent tubes. The highest attainable 4-meter visual acuity score is 100 letters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Median Change in Best Corrected Visual Acuity From 6 to12 Months</measure>
    <time_frame>6 to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Mean Change in Foveal Retinal Thickness From Baseline at 7 Days, and at Months 3, 6, 9, and 12</measure>
    <time_frame>7 days, and at months 3, 6, 9, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Incidence of Uveitis Flares (&gt; 2+ Cells in the Anterior Chamber or Vitreous)</measure>
    <time_frame>Study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Incidence of Ocular and Non-ocular Adverse Events</measure>
    <time_frame>Study duration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Uveitis</condition>
  <condition>Cytoid Macular Edema</condition>
  <arm_group>
    <arm_group_label>Ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.</description>
    <arm_group_label>Ranibizumab</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study

          -  Age ≥ 18 years

          -  A history of non-infectious uveitis with chronic cystoid macular edema (&gt; 3 months
             duration)

          -  Foveal retinal thickness of ≥ 300 µM by OCT testing

          -  One prior trial of oral or regional steroid treatment for CME ≥ 30 days prior to study
             enrollment with persistent CME (≥ 300 µM foveal retinal thickness on OCT) or inability
             to use steroid injections due to a history of increased IOP above 30 mmHg thought to
             be due to topical steroid treatment or prior steroid injections

          -  Anterior chamber and vitreous inflammation at the trace or below level according to
             the standardized classification of inflammation

          -  BCVA at 4 m using the ETDRS chart of 20/40 to 20/400 (Snellen equivalent) in the study
             eye

          -  Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT
             testing and retinal photography

        Exclusion Criteria:

          -  Pregnancy (positive pregnancy test) or known to be pregnant, or premenopausal but not
             using adequate contraception

          -  Treatment for CME with oral or steroid injections, Macugen, or Avastin within 6 weeks
             prior to enrollment in this study. Study subjects will be allowed to continue their
             immunomodulatory treatment for uveitis throughout the study.

          -  Previous vitrectomy

          -  Active intraocular inflammation in the study eye (greater than trace anterior chamber
             or vitreous cells)

          -  Current vitreous hemorrhage

          -  Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either
             eye

          -  Known allergy to any component of the study drug

          -  Intraocular pressure &gt; 30 mm Hg despite treatment with glaucoma medications

          -  Blood pressure &gt; 180/110 (systolic above 180 OR diastolic above 110). If blood
             pressure is brought below 180/110 by anti-hypertensive treatment, the subject can
             become eligible.

          -  Major surgery planned during the next 6 months

          -  Any other condition that the investigator believes would pose a significant hazard to
             the subject if the investigational therapy were initiated

          -  Participation in another simultaneous medical investigation or trial

          -  Unwilling or unable to follow or comply with all study related procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nisha Acharya, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Proctor Foundation, UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2007</study_first_submitted>
  <study_first_submitted_qc>July 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2007</study_first_posted>
  <results_first_submitted>June 20, 2012</results_first_submitted>
  <results_first_submitted_qc>September 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 21, 2012</results_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uveitis</keyword>
  <keyword>cytoid macular edema</keyword>
  <keyword>steroid</keyword>
  <keyword>Lucentis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from the F.I. Proctor Foundation Uveitis Clinica at University of California San Francisco.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ranibizumab for Macular Edema</title>
          <description>This study was an open-label, single-center, prospective, nonrandomized interventional case series of 7 eyes in 7 patients with controlled uveitis and persistent visually significant macular edema.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ranibizumab for Macular Edema</title>
          <description>This study was an open-label, single-center, prospective, nonrandomized interventional case series of 7 eyes in 7 patients with controlled uveitis and persistent visually significant macular edema.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.4" spread="15.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Mean Change at 3 Months in BSCVA From Baseline</title>
        <description>The outcome measure was mean best spectacle-corrected visual acuity (BSCVA). In this study, BSCVA was measured after trial frame manifest refraction, using high-contrast modified Bailey-Lovie (ETDRS) charts at 4 meters. The charts were placed in a retro-illuminated light box equipped with two 20-watt fluorescent tubes. The highest attainable 4-meter visual acuity score is 100 letters.</description>
        <time_frame>baseline and 3 months</time_frame>
        <population>6 patients completed all assessment points. One patient decided not to continue for nonmedical reasons, but they did complete the baseline, 1-week and 1-month assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab for Macular Edema</title>
            <description>This study was an open-label, single-center, prospective, nonrandomized interventional case series of 7 eyes in 7 patients with controlled uveitis and persistent visually significant macular edema.</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Change at 3 Months in BSCVA From Baseline</title>
          <description>The outcome measure was mean best spectacle-corrected visual acuity (BSCVA). In this study, BSCVA was measured after trial frame manifest refraction, using high-contrast modified Bailey-Lovie (ETDRS) charts at 4 meters. The charts were placed in a retro-illuminated light box equipped with two 20-watt fluorescent tubes. The highest attainable 4-meter visual acuity score is 100 letters.</description>
          <population>6 patients completed all assessment points. One patient decided not to continue for nonmedical reasons, but they did complete the baseline, 1-week and 1-month assessment.</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="3" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Median Change in Best Corrected Visual Acuity From 6 to12 Months</title>
        <time_frame>6 to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab</title>
            <description>Ranibizumab: 0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.</description>
          </group>
        </group_list>
        <measure>
          <title>The Median Change in Best Corrected Visual Acuity From 6 to12 Months</title>
          <units>Letters</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" lower_limit="-6" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Change in Foveal Retinal Thickness From Baseline at 7 Days, and at Months 3, 6, 9, and 12</title>
        <time_frame>7 days, and at months 3, 6, 9, and 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab</title>
            <description>Ranibizumab: 0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Change in Foveal Retinal Thickness From Baseline at 7 Days, and at Months 3, 6, 9, and 12</title>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-267" lower_limit="-620" upper_limit="-158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-356" lower_limit="-1034" upper_limit="-95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-354" lower_limit="-1053" upper_limit="-85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-243" lower_limit="-941" upper_limit="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-388" lower_limit="-1026" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Incidence of Uveitis Flares (&gt; 2+ Cells in the Anterior Chamber or Vitreous)</title>
        <time_frame>Study duration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab</title>
            <description>Ranibizumab: 0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.</description>
          </group>
        </group_list>
        <measure>
          <title>The Incidence of Uveitis Flares (&gt; 2+ Cells in the Anterior Chamber or Vitreous)</title>
          <units>uveitis flares</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Incidence of Ocular and Non-ocular Adverse Events</title>
        <time_frame>Study duration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab</title>
            <description>Ranibizumab: 0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.</description>
          </group>
        </group_list>
        <measure>
          <title>The Incidence of Ocular and Non-ocular Adverse Events</title>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ranibizumab for Macular Edema</title>
          <description>This study was an open-label, single-center, prospective, nonrandomized interventional case series of 7 eyes in 7 patients with controlled uveitis and persistent visually significant macular edema.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Subconjunctival Hemorrhage</sub_title>
                <description>Transient subconjunctival hemorrhage, or burst blood vessel, after intravitreal injection.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations of the study include a small sample size and lack of a control group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Nisha Acharya</name_or_title>
      <organization>University of California San Francisco</organization>
      <phone>415-476-8131</phone>
      <email>nisha.acharya@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

